Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort descending | Description |
---|---|---|---|---|---|---|---|---|
QUETIAPINE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/System Suitability | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In Resolution: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks |
METAXALONE | IDENTIFICATION/B. | USP41–NF36 | 2611 | 29-Mar-2019 | 1-Apr-2019 | NA | NA | Change The retention time of the major peak of the Sample solution corresponds to that of the Sample solution, as obtained in the Assay. to: The retention time of the major peak of the Sample solution corresponds to that of… Read More |
ONDANSETRON ORAL SOLUTION | USP Reference standards <11> | USPNF Online | Online | 25-Mar-2022 | 1-Apr-2022 | NA | NA | Change USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one. USP… Read More |
SODIUM BICARBONATE | IMPURITIES/Carbonate | USP42–NF37 | 4019 | 28-Jun-2019 | 1-Jul-2019 | NA | NA | In Analysis: Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate |
POTASSIUM GLUCONATE | IMPURITIES/Reducing Substances | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | NA | In Titrimetric system: Change Titrant: Iodine Back-titrant: Sodium thiosulfate to: Titrant: 0.1 N Iodine VS Back-titrant: 0.1 N Sodium Thiosulfate VS |
2,5-DIHYDROXYBENZOIC ACID | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6097 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change [303-07-1]. to: [490-79-9]. |
POLYETHYLENE GLYCOL STANDARDS WITH MOLECULAR WEIGHTS OF 1000, 2000, 3000, 4000, AND 6000 DALTONS (G/MOL) | CHEMICAL INFORMATION | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | Change CAS RN®: 25332-68-3. to: CAS RN®: 25322-68-3. |
POLYOXYL 35 CASTOR OIL | IDENTIFICATION/C. Identity by Fatty Acid Composition | USP43–NF38 | 5956 | 24-Apr-2020 | 1-May-2020 | NA | NA | In System suitability/Suitability requirements/Relative standard deviation: Change linoeate to: linoleate |
<3> TOPICAL AND TRANSDERMAL DRUG PRODUCTS—PRODUCT QUALITY TESTS | SPECIFIC TESTS FOR TDS | USPNF Online | Online | 28-Jul-2023 | 1-Dec-2023 | NA | NA | In Release Liner Peel Test: Change The product fails the test if the mean peel force is outside the acceptable range determined during product development. to: The product fails the test if the overall mean peel force is outside the acceptable range… Read More |
TELMISARTAN TABLETS | IDENTIFICATION/A. | USP43–NF38 | 4240 | 25-Sep-2020 | 1-Oct-2020 | NA | NA | Change Spectroscopic Identification Tests 〈197〉, Ultraviolet Spectroscopy: 197U: to: Spectroscopic Identification Tests 〈197〉, Ultraviolet-Visible Spectroscopy: 197U: |
ACARBOSE | IMPURITIES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In Chromatographic Purity/Analysis: Change Result = (rU/rA) × (1/F) × 100 to: Result = (rU/rA) × (1/F) |
CARVEDILOL | IMPURITIES/Organic Impurities, Procedure 2 | USP43–NF38 | Online | 18-Dec-2020 | 1-Jan-2021 | NA | NA | In Table 3/footnote b: Change 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(6,7,8,9-tetrahydro-5H-carbazol-4-yloxy)propan-2-ol. to: 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1H-carbazol-5-yloxy)propan-2-ol. |
DACTINOMYCIN | CHEMICAL INFORMATION | USP43–NF38 | Online | 25-Jun-2021 | 1-Jul-2021 | NA | NA | Please see the updated chemical structure at online.uspnf.com |
TRIAZOLAM TABLETS | Uniformity of dosage units <905> | USP41–NF36 | 4202 | 28-Dec-2018 | 1-Jan-2019 | NA | NA | In Mobile phase and Chromatographic system: Change Proceed as directed in the Assay under Triazolam. to: Proceed as directed in the Assay. AND In Procedure: Change Proceed as directed for Procedure… Read More |
ONDANSETRON | USP Reference standards <11> | USPNF 2021 ISSUE 1 | Online | 31-Dec-2021 | 1-Jan-2022 | NA | NA | Change USP Ondansetron RS USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one. USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one. to: USP… Read More |
CLOMIPHENE CITRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1068 | 31-May-2019 | 1-Jun-2019 | NA | NA | In USP Clomiphene Related Compound A RS: Change (E,Z)-2-[4-(1,2-Diphenylethyl)phenoxy]-N,N-diethylethanamine hydrochloride. to: (E,Z)-2-[4-(1,2-Diphenylvinyl)phenoxy]-N,N-diethylethanamine… Read More |
IVERMECTIN | CHEMICAL INFORMATION | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | Change C48H74O14(Component H2B1a) 875.09 C47H72O14(Component H2B1b) 861.07 Component H2B1a: Avermectin… Read More |
FEXOFENADINE HYDROCHLORIDE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official November 01, 2018) | Online | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic… Read More |
CALCIUM UNDECYLENATE | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Solution A: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows.… Read More |
EPINEPHRINE | IMPURITIES/Enantiomeric Purity | USP43–NF38 | Online | 24-Apr-2020 | 1-May-2020 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. In System suitability solution: Change 0.03 mg/mL of in Mobile phase to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in Mobile phase |
ACARBOSE TABLETS | IDENTIFICATION/B. | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Change The spectrum obtained from the Sample solution shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm–1. to: The spectrum obtained from the sample preparation shows IR maxima in the regions of 3500–3200… Read More |
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE TABLETS | Assay | USP43–NF38 | 1439 | 26-Jun-2020 | 1-Jul-2020 | NA | NA | In Procedure: Change 694.83/676.83)(250)CA(rU/rS) in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate,… Read More |
VALGANCICLOVIR HYDROCHLORIDE | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Organic Impurities/Table 3/footnote c: Change 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]-2-hydroxypropyl methyl-L-valinate hydrochloride. to: 3-[(2-Amino-6-oxo-1,6-dihydropurin-9-yl)methoxy]-2-hydroxypropyl L… Read More |
<1228.1> DRY HEAT DEPYROGENATION | INTRODUCTION | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | Change parental manufacturing to: parenteral manufacturing |
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS | IMPURITIES/Organic Impurities | USP43–NF38 | Online | 26-Feb-2021 | 1-Mar-2021 | NA | NA | In the first variable definition list in Analysis: Change 522.93 to: 522.94 |
GEMCITABINE FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 2094 | 30-Jul-2021 | 1-Aug-2021 | NA | NA | In USP Cytosine RS: Change 2(1H)-Pyrimidinone, 4-amino-. to: Cytosine. |
SALIX SPECIES BARK POWDER | ADDITIONAL REQUIREMENTS | USP42–NF37 | 5189 | 25-Jan-2019 | 1-Feb-2019 | NA | NA | In Labeling: Change The label states the Latin binomial(s) of one or several Salix species included in the article. to: The label states the Latin binomial(s) of one or several Salix species included in the article. Dosage forms… Read More |
ONDANSETRON INJECTION | USP Reference standards <11> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride. AND… Read More |
EPRINOMECTIN | IMPURITIES/Organic Impurities/Acceptance criteria | USP42–NF37 | 1627 | 31-May-2019 | 1-Jun-2019 | NA | NA | In Total unknown impurities: Change NMT 1.0 to: NMT 1.0% |
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS | IMPURITIES/Limit of Homatropine Hydrobromide and Related Substances | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In Buffer: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1. |
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 487 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Bendamustine Related Compound B RS: Change 4-(1-Methyl-5-morpholino-1H-benzimidazol-2-yl)butanoic acid. C16H21N3O3 303.36 to: 4-(1-Methyl-5-morpholino-1H-benzimidazol-2-yl)… Read More |
PROPRANOLOL HYDROCHLORIDE | IMPURITIES/Organic Impurities | USP43–NF38 | 3746 | 24-Apr-2020 | 1-May-2020 | NA | NA | In System suitability/Suitability requirements/Relative standard deviation: Change NMT 5.0, to: NMT 5.0%, |
FLUVOXAMINE MALEATE TABLETS | ASSAY/Procedure | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Solution A: Change 8 g/L of 1-pentanesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-pentanesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water. |
SOTALOL HYDROCHLORIDE TABLETS | Identification | USP43–NF38 | 4105 | 31-Jul-2020 | 1-Aug-2020 | NA | NA | Change Weigh and powder a quantity of the Tablets, equivalent to about 250 mg of sotalol hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter: the filtrate so… Read More |
TELMISARTAN TABLETS | ASSAY | USPNF Online | Online | 27-Oct-2023 | 1-Nov-2023 | NA | NA | In Procedure/System suitability/Suitability requirements: Change Resolution: NLT 3 between telmisartan and telmisartan related compound A Tailing factor: NMT 2.0 for the telmisartan peak Capacity factor: NLT… Read More |
MEBENDAZOLE ORAL SUSPENSION | Identification | USP43–NF38 | 2744 | 20-Nov-2020 | 1-Dec-2020 | NA | NA | Change Mix a quantity of Oral Suspension, equivalent to about 200 mg of mebendazole, with 20 mL of a mixture of chloroform and 96 percent formic acid (19:1). Proceed as directed for Identification under Mebendazole Tablets, beginning with “Warm the… Read More |
AMITRIPTYLINE HYDROCHLORIDE | CHEMICAL INFORMATION | USP43–NF38 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | Change 313.86 to: 313.87 |
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 29-Oct-2021 | 1-Nov-2021 | NA | NA | In Analysis: Change rS = peak response of alfuzosin from the Sample solution to: rS = peak response of alfuzosin from the Standard solution |
LEVALBUTEROL HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 2518 | 26-Apr-2019 | 1-May-2019 | NA | NA | In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde. C13H19NO3 237.29 ▲[NOTE—This may be available as the sulfate salt (2:1).]▲ (USP… Read More |
MUPIROCIN CREAM | Related compounds/Table 1 | USPNF Online | Online | 29-Apr-2022 | 1-May-2022 | NA | NA | In footnote 2: Change 9-{(E)-4-[(2R,3aS,6S,7S,8aRS)-2-{(1RS,2S,3S)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2H-furo[3,2-c]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to:… Read More |
ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION | SPECIFIC TESTS/Microbial Enumeration Tests <61> and Tests for Specified Microorganisms <62> | USP42–NF37 | 170 | 26-Jul-2019 | 1-Aug-2019 | NA | NA | Change cfu/g to: cfu/mL |
TERAZOSIN CAPSULES | ASSAY/Procedure | USPNF Online | Online | 30-Sep-2022 | 1-Oct-2022 | NA | NA | In Hydrochloric acid solution: Change 0.1 N methanolic hydrochloric acid to: 0.01 N methanolic hydrochloric acid |
<121> INSULIN ASSAYS | ASSAY/Rabbit Blood Sugar Method—Quantitative | Revision Bulletin (Official May 01, 2019) | Online | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard stock solution: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In Sample stock solution: Change of USP Insulin RS of the appropriate species.… Read More |
LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJECTION | Assay for lidocaine hydrochloride | USPNF Online | Online | 24-Feb-2023 | 1-Mar-2023 | NA | NA | Change Proceed with Injection as directed in the Assay for lidocaine hydrochloride under Lidocaine and Epinephrine Injection. to: Proceed with Injection as directed in the Assay for lidocaine hydrochloride under Lidocaine… Read More |
PRAVASTATIN SODIUM | ADDITIONAL REQUIREMENTS | USP43–NF38 | 3645 | 29-May-2020 | 1-Jun-2020 | NA | NA | In USP Reference Standards <11>/USP Pravastatin Related Compound A RS: Change 446.51 to: 446.52 |
REAGENTS AND REFERENCE TABLES | Solutions/Test Solutions and Indicator Solutions/Starch TS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | Change Prepare this solution by one of the following procedures: to: Prepare this solution by one of the following procedures. Apply the Test for sensitivity to confirm suitability for freshly or previously prepared solutions or commercially bought… Read More |
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS | CONTAMINANTS | USP43–NF38 | 5378 | 30-Oct-2020 | 1-Nov-2020 | NA | NA | Change Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species and Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species: to: … Read More |
IODIXANOL INJECTION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | In USP Reference Standards 〈11〉/USP Iodixanol Related Compound E RS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-… Read More |
SERTRALINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF 2021 ISSUE 1 | Online | 26-Mar-2021 | 1-May-2021 | NA | NA | In USP Sertraline Hydrochloride Racemic Mixture RS: Change C17H17Cl2 · HCl to: C17H17Cl2N · HCl |
RIFABUTIN | IMPURITIES/Organic Impurities, Procedure 2 | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In Sample solution: Change 1 mg/mL of USP Rifabutin RS prepared as follows. to: 1 mg/mL of Rifabutin prepared as follows. |